The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration including as active ingredient thereof an agonist of the central receptor of benzodiazepinics chosen among diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam nitrazepam and midazolam maleate in a mixture with a pharmaceutical excipient consisting of at least 70% of the weight of the final formulation containing 40-45% by weight of lactose 15-27% by weight...

The present invention comprises a nanoparticulate composition comprising (a) a benzodiazepine having an effective average particle size of less than about 2000 nm wherein the benzodiazepine is selected from the group consisting of alprazolam brotizolam chlordiazepoxide clobazam clonazepam clorazepam demoxazepam flumazenil flurazepam halazepam midazolam nordazepam medazepam diazepam nitrazepam oxazepam midazepam prazepam quazepam triazolam temazepam loprazolam pharmaceutically acceptable salts an...

Una composición farmacéutica sublingual que comprende 0125-10% en peso de un agonista del receptor benzodiazepínico central seleccionado entre el grupo constituido por maleato de midazolam diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam y nitrazepam y conteniendo al menos el 70% en peso de la formulación final la siguiente mezcla ternaria i) 40-45% de lactosa ii) 15-27% de sorbitol y iii) 12-16% de celulosa.

FIELD medicine. ^ SUBSTANCE invention suggests pharmaceutical compositions intended for sublingual intake as active ingredient of which agonist of central receptor of benzodiazepines is used selected from the following list diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam nitrazepam midazolam-maleate in mixture with pharmaceutical excipient which constitutes at least 70% of total weight of ready composition and which contains lactose in amount from 40 to 45 wt % corbite in amount...

The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration including as active ingredient thereof an agonist of the central receptor of benzodiazepinics chosen among diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam nitrazepam and midazolam maleate in a mixture with a pharmaceutical excipient consisting of at least 70% of the weight of the final formulation containing 40-45% by weight of lactose 15-27% by weight...

The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration including as active ingredient thereof an agonist of the central receptor of benzodiazepinics chosen among diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam nitrazepam and midazolam maleate in a mixture with a pharmaceutical excipient consisting of at least 70% of the weight of the final formulation containing 40 - 45% by weight of lactose 15- 27% by wei...

Reivindicación 1: Una formulación farmacéutica administrada por vía oral caracterizada porque comprende uno o más ingredientes farmacéuticos activos (IFA) que opcionalmente comprende sus sales complejos profármacos y metabolitos que comprende cacao en polvo y porque él uno o más IFA se eligen(n) entre IFA adecuados para absorción oral. Reivindicación 2: Una formulación de acuerdo con la reivindicación 1 caracterizada porque él uno o más ingredientes farmacéuticos activos (IFA) se selecciona(n) d...

\COMPOSIçãO FARMACêUTICA A BASE DE UM AGONISTA DO RECEPTOR CENTRAL DE BENZODIAZEPìNICOS\". A presente invenção descreve o uso de compostos farmacêuticos em composições farmacêuticas para administração sublingual incluindo como princípio ativo dos mesmos um agonista do receptor central dos benzodiazepínicos escolhido entre diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam nitrazepam e maleato de midazolam em mistura com um excipiente farmac...

The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration including as active ingredient thereof an agonist of the central receptor of benzodiazepinics chosen among diazepam lorazepam bromazepam triazolam alprazolam flunitrazepam nitrazepam and midazolam maleate in a mixture with a pharmaceutical excipient consisting of at least 70% of the weight of the final formulation containing 40 - 45% by weight of lactose 15- 27% by wei...